A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors - Trial NCT06208410
Access comprehensive clinical trial information for NCT06208410 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Risen (Suzhou) Pharma Tech Co., Ltd. and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 306 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Risen (Suzhou) Pharma Tech Co., Ltd.
Timeline & Enrollment
Phase 1/2
Jan 11, 2024
Feb 26, 2026
Primary Outcome
Dose-limiting toxicity,MTD,RP2D,Incidence and severity of adverse events including serious adverse events
Summary
This study is an open-label, multicenter, Phase Ib/II clinical study to evaluate the safety,
 tolerability, pharmacokinetics, and preliminary efficacy of JS105 in combination with other
 anti-tumor therapies in patients with advanced solid tumors. Patients will be enrolled in two
 stages: a dose-escalation stage and a dose-expansion stage.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06208410
Non-Device Trial